Quinovic acidCAS# 465-74-7 |
Quality Control & MSDS
3D structure
Package In Stock
Number of papers citing our products
| Cas No. | 465-74-7 | SDF | Download SDF |
| PubChem ID | 120678 | Appearance | Powder |
| Formula | C30H46O5 | M.Wt | 486.7 |
| Type of Compound | Triterpenoids | Storage | Desiccate at -20°C |
| Solubility | Soluble in Chloroform,Dichloromethane,Ethyl Acetate,DMSO,Acetone,etc. | ||
| Chemical Name | (1S,2R,4aS,6aR,6aR,6bR,8aR,10S,12aR,14bS)-10-hydroxy-1,2,6b,9,9,12a-hexamethyl-2,3,4,5,6,6a,7,8,8a,10,11,12,13,14b-tetradecahydro-1H-picene-4a,6a-dicarboxylic acid | ||
| SMILES | CC1CCC2(CCC3(C(=CCC4C3(CCC5C4(CCC(C5(C)C)O)C)C)C2C1C)C(=O)O)C(=O)O | ||
| Standard InChIKey | OJUYFGQEMPENCE-DPKHZRJYSA-N | ||
| Standard InChI | InChI=1S/C30H46O5/c1-17-9-14-29(24(32)33)15-16-30(25(34)35)19(23(29)18(17)2)7-8-21-27(5)12-11-22(31)26(3,4)20(27)10-13-28(21,30)6/h7,17-18,20-23,31H,8-16H2,1-6H3,(H,32,33)(H,34,35)/t17-,18+,20+,21-,22+,23+,27+,28-,29+,30-/m1/s1 | ||
| General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
| About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
| Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. | ||
| Description | 1. Quinovic acid glycosides have a potent inhibitory effect on the growth of human bladder cancer cell lines by inducing apoptosis through modulation of NF-κB, suggests that it may become a potential therapeutic agent for the prevention and/or treatment of this cancer. 2. Quinovic acid shows some anti-tumour activities. |
| Targets | Caspase | NF-kB |
Quinovic acid Dilution Calculator
Quinovic acid Molarity Calculator
| 1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
| 1 mM | 2.0547 mL | 10.2733 mL | 20.5465 mL | 41.0931 mL | 51.3663 mL |
| 5 mM | 0.4109 mL | 2.0547 mL | 4.1093 mL | 8.2186 mL | 10.2733 mL |
| 10 mM | 0.2055 mL | 1.0273 mL | 2.0547 mL | 4.1093 mL | 5.1366 mL |
| 50 mM | 0.0411 mL | 0.2055 mL | 0.4109 mL | 0.8219 mL | 1.0273 mL |
| 100 mM | 0.0205 mL | 0.1027 mL | 0.2055 mL | 0.4109 mL | 0.5137 mL |
| * Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. | |||||
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
- Resibufogenin
Catalog No.:BCN5366
CAS No.:465-39-4
- Bufalin
Catalog No.:BCN1046
CAS No.:465-21-4
- Polyporenic acid C
Catalog No.:BCN3645
CAS No.:465-18-9
- Oleandrin
Catalog No.:BCN5511
CAS No.:465-16-7
- Neritaloside
Catalog No.:BCN5509
CAS No.:465-13-4
- Gamabufotalin
Catalog No.:BCN2358
CAS No.:465-11-2
- Germanicol
Catalog No.:BCN7507
CAS No.:465-02-1
- Arjunolic acid
Catalog No.:BCN5508
CAS No.:465-00-9
- Pseudotaraxasterol
Catalog No.:BCN5507
CAS No.:464-98-2
- Asiatic acid
Catalog No.:BCN5506
CAS No.:464-92-6
- Conquinamine
Catalog No.:BCN6622
CAS No.:464-86-8
- Quinamine
Catalog No.:BCN6590
CAS No.:464-85-7
- Marrubiin
Catalog No.:BCC8208
CAS No.:465-92-9
- Hederagenin
Catalog No.:BCN5513
CAS No.:465-99-6
- alpha-Spinasterol acetate
Catalog No.:BCN5510
CAS No.:4651-46-1
- Cycloartanol
Catalog No.:BCN4860
CAS No.:4657-58-3
- Hederagonic acid
Catalog No.:BCN5514
CAS No.:466-01-3
- Hedragonic acid
Catalog No.:BCN6911
CAS No.:466-02-4
- Proscillaridin A
Catalog No.:BCC8239
CAS No.:466-06-8
- Uzarigenin
Catalog No.:BCN5515
CAS No.:466-09-1
- Benzoylaconine
Catalog No.:BCN5400
CAS No.:466-24-0
- Bullatine B
Catalog No.:BCN2375
CAS No.:466-26-2
- Rauvomitin
Catalog No.:BCN3421
CAS No.:466-57-9
- Cryptomeridiol
Catalog No.:BCN5516
CAS No.:4666-84-6
Quinovic acid glycosides purified fraction from Uncaria tomentosa induces cell death by apoptosis in the T24 human bladder cancer cell line.[Pubmed:24607820]
Food Chem Toxicol. 2014 May;67:222-9.
Bladder cancer is the second most prevalent malignancy in the genitourinary tract and remains a therapeutic challenge. In the search for new treatments, researchers have attempted to find compounds with low toxicity. With this goal in mind, Uncaria tomentosa is noteworthy because the bark and root of this species are widely used in traditional medicine and in adjuvant therapy for the treatment of numerous diseases. The objective of this study was to investigate the antitumor effect of one purified bioactive fraction of U.tomentosa bark on cell proliferation in two human bladder cancer cell lines, T24 and RT4. Quinovic acid glycosides purified fraction (QAPF) of U.tomentosa decreased the growth and viability of both T24 and RT4 cell lines. In T24 cells, QAPF induced apoptosis by activating caspase-3 and NF-kappaB. Further study showed that this fraction does not induce cell cycle arrest and does not alter PTEN and ERK levels. In conclusion, we demonstrated that QAPF of U.tomentosa has a potent inhibitory effect on the growth of human bladder cancer cell lines by inducing apoptosis through modulation of NF-kappaB, and we suggest that QAPF may become a potential therapeutic agent for the prevention and/or treatment of this cancer.
Hypotensive and bradycardic effects of quinovic acid glycosides from Aspidosperma fendleri in spontaneously hypertensive rats.[Pubmed:25920261]
Nat Prod Commun. 2015 Feb;10(2):281-4.
The Aspidosperma genus (Apocynaceae) represents one of the largest sources of indole alkaloids widely associated with cardiovascular effects. Aspidosperma fendleri, a plant found mainly in Venezuela, has a single phytochemical report in which is revealed the presence of alkaloids in its seeds. This study explored the cardiovascular effects of an ethanolic extract of A. fendleri leaves (EEAF) in spontaneously hypertensive rats (SHR) and its potential bioactive compounds. Using bioguided fractionation, fractions and pure compounds were intravenously administered to SHR and their effects on mean arterial blood pressure (MABP) and heart rate (HR) monitored over time. EEAF induced hypotensive and bradycardic effects as shown by significant reductions in mean arterial blood pressure (MABP) and heart rate (HR), respectively. Bioactivity-guided fractionation led to the isolation of a mixture of two known isomeric triterpenoid glycosides identified by spectral evidence as Quinovic acid 3-O-beta-rhamnopyranoside and Quinovic acid 3-O-beta-fucopyranoside. This mixture of triterpenoid saponins induced reductions in MABP and HR similar to those induced by propranolol. Together, these findings indicate that the two Quinovic acid glycosides are responsible for the hypotensive and bradycardic effects which suggest their potential use in cardiovascular therapy.
